Sangamo Therapeutics (SGMO) Tops Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. PLTR
6. CSCO
7. KTOS
8. LDOS
9. LBRX
10. BMY

Go back to Sangamo Therapeutics (SGMO) Tops Q1 EPS by 1c

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

May 5, 2022 4:01 PM EDT

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.

This quarter, we have continued to progress multiple programs through clinical development and demonstrated, once again, Sangamos track record of advancing groundbreaking therapies in genomic medicine, said Sandy Macrae, Chief Executive Officer of Sangamo. We dosed a total of five patients across three programs, including the first patient in our study for the... More